Diagnostic Method Patents and Harms to Follow-On Innovation

22 Pages Posted: 10 Oct 2014

See all articles by Rachel Sachs

Rachel Sachs

Washington University in Saint Louis - School of Law

Date Written: October 1, 2012

Abstract

In a series of cases over the past decade, the Federal Circuit and Supreme Court have confronted the patent eligibility of broadly claimed diagnostic methods under ยง 101 of the Patent Act. These diagnostic method patents claim processes that, generally speaking, first identify a biomarker and then use correlations associated with that biomarker for diagnostic purposes. This Note argues that granting these kinds of broad claims to natural correlations creates unique harms to follow-on innovation, ones that do not occur with other types of patents. Yet these harms have not been specified in the literature or the case law. In light of both these unique harms and the lack of attendant benefits, the Federal Circuit and Supreme Court should revise their approaches to broad diagnostic method patents.

Suggested Citation

Sachs, Rachel, Diagnostic Method Patents and Harms to Follow-On Innovation (October 1, 2012). Harvard Law Review, Vol. 126, No. 5, p. 1370, 2013. Available at SSRN: https://ssrn.com/abstract=2505766

Rachel Sachs (Contact Author)

Washington University in Saint Louis - School of Law ( email )

Campus Box 1120
St. Louis, MO 63130
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
84
Abstract Views
808
rank
307,837
PlumX Metrics